Open Access
ARTICLE
RCN3 Expression Indicates Prognosis in Colorectal Cancers
Shengzhe Ma1,#, Xiaoming Zhu1,#, Cheng Xin1,#, Fuao Cao1, Mengnan Xu1, Xiangling Han1, Jinke Sui3,*, Wenjun Chang2,*, Wei Zhang1,*
1
Department of Colorectal Surgery, Changhai Hospital, Shanghai, 200433, China
2
Department of Environmental Health, Naval Medical University, Shanghai, 200433, China
3
Jiahui International Cancer Center, Jiahui International Hospital, Shanghai, 200433, China
* Corresponding Authors: Jinke Sui. Email: ; Wenjun Chang. Email: ; Wei Zhang. Email:
# Contributed equally to this work
Oncologie 2022, 24(4), 823-833. https://doi.org/10.32604/oncologie.2022.025411
Received 10 July 2022; Accepted 22 September 2022; Issue published 31 December 2022
Abstract
Background: Reticulocalbin 3 (RCN3) has been associated with several malignancies. However, its role in colorectal cancer (CRC) remains controversial. Thus, this study aimed to investigate the role of RCN3 in CRC prognosis.
Methods: The clinical significance of RCN3 expression in CRC was evaluated in a large cohort of
483 patients. Normal tissues, carcinoma, para-carcinoma, adenoma, and metastatic tissues were evaluated by
immunohistochemistry. We investigated the association between RCN3 expression and CRC occurrence in
tumors and other tissues. Prognostic factors were also evaluated by Kaplan-Meier survival analysis and the
Cox regression model.
Results: RCN3 was significantly overexpressed in CRC and metastatic tissues. Patients
with high RCN3 expression had shorter disease-free survival than those with low RCN3 expression. Multivariate
Cox regression analysis showed a risk ratio HR], 0.607; confidence interval [CI], 0.362–1.016;
p < 0.05 after adjusting for other prognostic factors. HighRCN3 expression was also associated with a worse chemotherapeutic
response in the colon (
p < 0.01) or rectal (
p < 0.05) cancer patients who received adjuvant chemotherapy.
Conclusion: RCN3 expression level is an independent risk factor and serves as a prognostic biomarker for CRC. High
RCN3 expression predicts poor prognosis and chemotherapeutic response.
Keywords
Cite This Article
Ma, S., Zhu, X., Xin, C., Cao, F., Xu, M. et al. (2022). RCN3 Expression Indicates Prognosis in Colorectal Cancers.
Oncologie, 24(4), 823–833. https://doi.org/10.32604/oncologie.2022.025411